Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean G Buchanan

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Current Opinion in Drug Discovery & Development|June 13, 2002
Structural genomics: bridging functional genomics and structure-based drug designSean G Buchanan
Oncotarget|January 11, 2019
Unraveling the genomic determinants of response to CDK4/6 inhibitorsLacey M Litchfield, Vue W Webster, Sean G Buchanan
Cancer Research|July 21, 2010
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growthYu-Wen Zhang, Ben Staal, Curt Essenburg, et al.
Molecular Cancer Therapeutics|August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulationVipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Structure (London, England : 1993)|November 14, 2002
Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase: a 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzymeBrian W Noland, Janet M Newman, Jörg Hendle, et al.
Oncotarget|May 12, 2020
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cellsLacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, et al.
Nature Cancer|September 27, 2021
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degradersXuewei Wu, Xiaobao Yang, Yan Xiong, et al.
The Journal of Biological Chemistry|October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinaseShane Atwell, Jason M Adams, John Badger, et al.
The EMBO Journal|December 20, 2003
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulatorHal A Lewis, Sean G Buchanan, Stephen K Burley, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Opinion in Drug Discovery & Development|June 13, 2002
Structural genomics: bridging functional genomics and structure-based drug designSean G Buchanan
Oncotarget|January 11, 2019
Unraveling the genomic determinants of response to CDK4/6 inhibitorsLacey M Litchfield, Vue W Webster, Sean G Buchanan
Cancer Research|July 21, 2010
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growthYu-Wen Zhang, Ben Staal, Curt Essenburg, et al.
Molecular Cancer Therapeutics|August 15, 2014
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulationVipin Yadav, Teresa F Burke, Lysiane Huber, et al.
Structure (London, England : 1993)|November 14, 2002
Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase: a 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzymeBrian W Noland, Janet M Newman, Jörg Hendle, et al.
Oncotarget|May 12, 2020
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cellsLacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, et al.
Nature Cancer|September 27, 2021
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degradersXuewei Wu, Xiaobao Yang, Yan Xiong, et al.
The Journal of Biological Chemistry|October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinaseShane Atwell, Jason M Adams, John Badger, et al.
The EMBO Journal|December 20, 2003
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulatorHal A Lewis, Sean G Buchanan, Stephen K Burley, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Pageof 2